TRLS-03. PHASE II TRIAL OF GDC-0084 IN COMBINATION WITH TRASTUZUMAB FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BCBM)

BACKGROUND: The PI3K/Akt/mTOR is an important pathway in BCBM. Mutations in PIK3CA or PTEN loss are associated with trastuzumab resistance. Inhibition of PI3K and mTOR led to durable responses in 3 of 5 patient-derived xenografts (PDX) models of BCBM. GDC-0084 is a potent, brain-penetrant inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Leone, Jose Pablo, Trippa, Lorenzo, Milisits, Lindsey, Andrews, Chelsea, Ligibel, Jennifer, Parsons, Heather, Bi, Wenya, Zhao, Jean, Winer, Eric, Lin, Nancy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213424/
http://dx.doi.org/10.1093/noajnl/vdz014.036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213424/
http://dx.doi.org/10.1093/noajnl/vdz014.036

Ejemplares similares